PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF PROSTATE CANCER
The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound mahanine from Murraya koenigii.
1 - 10 . (canceled)
11 . A method of inducing apoptosis of cultured prostate cancer cells comprising treating the cultured prostate cancer cells with a pharmaceutical composition comprising a therapeutically effective amount of the compound mahanine or a pharmaceutically acceptable salt of the compound mahanine.
12 . The method of claim 11 , further comprising administering a pharmaceutically acceptable carrier.
13 . The method of claim 12 , wherein the carrier is selected from the group consisting of proteins, carbohydrates, sugar, magnesium stearate, cellulose, calcium carbonate, and starch-gelatin paste and pharmaceutical acceptable carriers, excipient, diluent, and solvent.
14 . The method of claim 11 , wherein the compound mahanine is obtained from an extract of Murraya Koenigii.
15 . The method of claim 11 , wherein the compound mahanine is synthetically made.
16 - 18 . (canceled)
19 . The method of claim 11 , wherein the pharmaceutical composition kills the cultured prostate cancer cells, the cultured prostate cancer cells being an androgen-independent cell line PC 3 or an androgen-dependent cell line LNCaP, in a dose and time dependent manner.
20 . The method of claim 11 , wherein the pharmaceutical composition inhibits phosphorylation of Akt in a dose and time dependent manner.
21 - 24 . (canceled)